Harmony Biosciences Holdings, Inc.HRMYNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
9.58%
↓ 57% below average
Average (26q)
22.14%
Historical baseline
Range
High:220.08%
Low:-90.58%
Volatility
1403.4%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 9.58% |
| Q2 2025 | 45.22% |
| Q1 2025 | -0.36% |
| Q4 2024 | 36.55% |
| Q3 2024 | -60.07% |
| Q2 2024 | 186.55% |
| Q1 2024 | -26.78% |
| Q4 2023 | 73.19% |
| Q3 2023 | 16.90% |
| Q2 2023 | 12.64% |
| Q1 2023 | 31.68% |
| Q4 2022 | -75.11% |
| Q3 2022 | 220.08% |
| Q2 2022 | 67.17% |
| Q1 2022 | 1.70% |
| Q4 2021 | -36.53% |
| Q3 2021 | 80.66% |
| Q2 2021 | 38.88% |
| Q1 2021 | -38.59% |
| Q4 2020 | 80.12% |
| Q3 2020 | 1.46% |
| Q2 2020 | 21.51% |
| Q1 2020 | -52.84% |
| Q4 2019 | 67.80% |
| Q3 2019 | -13.16% |
| Q2 2019 | -90.58% |
| Q1 2019 | 0.00% |